Bifogade filer
PDF
Beskrivning
| Land | Sverige |
|---|---|
| Lista | First North Stockholm |
| Sektor | Hälsovård |
| Industri | Bioteknik |
Intresserad av bolagets nyckeltal?
Analysera bolaget i Börsdata!
Vem äger bolaget?
All ägardata du vill ha finns i Holdings!
Gothenburg, May 13, 2026 - Elicera Therapeutics AB (publ), a clinical stage cell and gene therapy company developing next generation cancer treatments based on oncolytic viruses and CAR T-cell therapies, armed with immune-activating properties via the company's commercially available iTANK platform, announces today that the Company's co-founder, Chief Scientific Officer (CSO) and board member Professor Magnus Essand is taking temporary leave from his duties in the Company in order to undergo medical treatment. Di Yu is appointed Acting CSO.
CEO Jamal El-Mosleh comments:
"Magnus has started treatment and will not be participating in the Company's operations or board work for the foreseeable future. To ensure continuity and progress in the business, Di Yu has temporarily taken over the role of Acting Chief Scientific Officer (CSO) with immediate effect."
Di Yu has, in recent years, held the greatest operational responsibility for the Company's scientific and clinical development. He has been deeply involved in the day-to-day management of the research and development programs. Magnus Essand has played a central role in the planning and design of the CARMA study (ELC-301) and the planned glioblastoma study (ELC-401). These study designs are now finalized, which is why Magnus Essand's operational involvement has gradually decreased thereafter.
Elicera has, in recent years, systematically strengthened the organization to reduce dependence on individual key persons. The Company has recruited several senior researchers internally from academia as well as external expertise, including a senior clinical project manager with extensive experience from early-phase oncology studies.
The Company's operational activities, including the ongoing CARMA study and preparations for the clinical study with ELC-401, continue according to the established plan.
"The Board and management would like to emphasize that Elicera has a strong and well-equipped organization that is ready to drive the development of the Company's drug candidates forward. The Company wishes Magnus Essand all strength and support during his treatment and will now continue the operations that build on his invaluable contributions to Elicera since the Company was founded," continues Jamal El-Mosleh.